Fundraising FoxAecorBio
Menlo Park, US · Founded 2023 · Delaware corporation
Find your way into AecorBio
Sign up to see every warm intro you have to AecorBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AecorBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AecorBio is an IND-stage biopharmaceutical company that has built a high-throughput peptide drug discovery platform targeting drug-resistance mechanisms in oncology, immunology, and neurology. Its lead candidate, FT-002a, is an orally available peptide co-therapeutic aimed at restoring androgen receptor inhibitor sensitivity in castration-resistant prostate cancer.
Founders & leadership
BF
Bomi FramrozeExecutive
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2025
▶$2.5MraisedNov 2025 · 20 investors · BiotechnologyRule 506(b)
▶$2.5MraisedNov 2025 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bomi FramrozeExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Helicore BiopharmaHelicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Ochre BioOchre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.
Companies working in the same space as AecorBio.
Frequently asked questions
- What does AecorBio do?
- AecorBio is an IND-stage biopharmaceutical company that has built a high-throughput peptide drug discovery platform targeting drug-resistance mechanisms in oncology, immunology, and neurology. Its lead candidate, FT-002a, is an orally available peptide co-therapeutic aimed at restoring androgen receptor inhibitor sensitivity in castration-resistant prostate cancer.
- How much funding has AecorBio raised?
- AecorBio has disclosed $2.5M raised across 1 round.
- Where is AecorBio headquartered?
- AecorBio is headquartered in Menlo Park, US.